StreetInsider.com News Articles

Form 8-K PAVmed Inc. For: Aug 14

Fri, 14 Aug 2026 10:45:00 -0400

si-local-file:///var/storage/secattach/20260814/26926744.html

Form 8-K PAVmed Inc. For: Aug 14

Fri, 14 Aug 2026 10:45:00 -0400

si-local-file:///var/storage/secattach/20260814/26926744.html

PAVmed Provides Business Update and Reports Second Quarter 2026 Financial Results

Fri, 14 Aug 2026 08:00:00 -0400

Veris Health accelerated its commercial engagement with OSU-The James

Veris Health implantable physiological monitor achieved development milestones towards upcoming FDA submission

Lucid Diagnostics secured first laboratory benefit manager coverage policy for EsoGuard ^®

Conference call and webcast to be held today, August 14, at 8:30 AM EDT

NEW YORK, Aug. 14, 2026 /PRNewswire/ -- PAVmed Inc. (NASDAQ: PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors, today provided a business

PAVmed Provides Business Update and Reports Second Quarter 2026 Financial Results

Fri, 14 Aug 2026 08:00:00 -0400

Veris Health accelerated its commercial engagement with OSU-The James

Veris Health implantable physiological monitor achieved development milestones towards upcoming FDA submission

Lucid Diagnostics secured first laboratory benefit manager coverage policy for EsoGuard ^®

Conference call and webcast to be held today, August 14, at 8:30 AM EDT

PAVmed Provides Business Update and Reports Second Quarter 2026 Financial Results

Fri, 14 Aug 2026 08:00:00 -0400

Veris Health accelerated its commercial engagement with OSU-The James

Veris Health implantable physiological monitor achieved development milestones towards upcoming FDA submission

Lucid Diagnostics secured first laboratory benefit manager coverage policy for EsoGuard ^®

Conference call and webcast to be held today, August 14, at 8:30 AM EDT

PAVmed Provides Business Update and Reports Second Quarter 2026 Financial Results

Fri, 14 Aug 2026 08:00:00 -0400

Veris Health accelerated its commercial engagement with OSU-The James

Veris Health implantable physiological monitor achieved development milestones towards upcoming FDA submission

Lucid Diagnostics secured first laboratory benefit manager coverage policy for EsoGuard ^®

Conference call and webcast to be held today, August 14, at 8:30 AM EDT

PAVmed Provides Business Update and Reports Second Quarter 2026 Financial Results

Fri, 14 Aug 2026 08:00:00 -0400

Veris Health accelerated its commercial engagement with OSU-The James

Veris Health implantable physiological monitor achieved development milestones towards upcoming FDA submission

Lucid Diagnostics secured first laboratory benefit manager coverage policy for EsoGuard ^®

Conference call and webcast to be held today, August 14, at 8:30 AM EDT

PAVmed Provides Business Update and Reports Second Quarter 2026 Financial Results

Fri, 14 Aug 2026 08:00:00 -0400

Veris Health accelerated its commercial engagement with OSU-The James

Veris Health implantable physiological monitor achieved development milestones towards upcoming FDA submission

Lucid Diagnostics secured first laboratory benefit manager coverage policy for EsoGuard ^®

Conference call and webcast to be held today, August 14, at 8:30 AM EDT

PAVmed Provides Business Update and Reports Second Quarter 2026 Financial Results

Fri, 14 Aug 2026 08:00:00 -0400

Veris Health accelerated its commercial engagement with OSU-The James

Veris Health implantable physiological monitor achieved development milestones towards upcoming FDA submission

Lucid Diagnostics secured first laboratory benefit manager coverage policy for EsoGuard ^®

Conference call and webcast to be held today, August 14, at 8:30 AM EDT

PAVmed Provides Business Update and Reports Second Quarter 2026 Financial Results

Fri, 14 Aug 2026 08:00:00 -0400

Veris Health accelerated its commercial engagement with OSU-The James

Veris Health implantable physiological monitor achieved development milestones towards upcoming FDA submission

Lucid Diagnostics secured first laboratory benefit manager coverage policy for EsoGuard ^®

Conference call and webcast to be held today, August 14, at 8:30 AM EDT

PAVmed Provides Business Update and Reports Second Quarter 2026 Financial Results

Fri, 14 Aug 2026 08:00:00 -0400

Veris Health accelerated its commercial engagement with OSU-The James

Veris Health implantable physiological monitor achieved development milestones towards upcoming FDA submission

Lucid Diagnostics secured first laboratory benefit manager coverage policy for EsoGuard ^®

Conference call and webcast to be held today, August 14, at 8:30 AM EDT

PAVmed Provides Business Update and Reports Second Quarter 2026 Financial Results

Fri, 14 Aug 2026 08:00:00 -0400

Veris Health accelerated its commercial engagement with OSU-The James

Veris Health implantable physiological monitor achieved development milestones towards upcoming FDA submission

Lucid Diagnostics secured first laboratory benefit manager coverage policy for EsoGuard ^®

Conference call and webcast to be held today, August 14, at 8:30 AM EDT

PAVmed Provides Business Update and Reports Second Quarter 2026 Financial Results

Fri, 14 Aug 2026 08:00:00 -0400

Veris Health accelerated its commercial engagement with OSU-The James

Veris Health implantable physiological monitor achieved development milestones towards upcoming FDA submission

Lucid Diagnostics secured first laboratory benefit manager coverage policy for EsoGuard ^®

Conference call and webcast to be held today, August 14, at 8:30 AM EDT

PAVmed Provides Business Update and Reports Second Quarter 2026 Financial Results

Fri, 14 Aug 2026 08:00:00 -0400

Veris Health accelerated its commercial engagement with OSU-The James

Veris Health implantable physiological monitor achieved development milestones towards upcoming FDA submission

Lucid Diagnostics secured first laboratory benefit manager coverage policy for EsoGuard ^®

Conference call and webcast to be held today, August 14, at 8:30 AM EDT

Form SCHEDULE 13G/A PAVmed Inc. Filed by: NAGELBERG DAVID S

Thu, 13 Aug 2026 19:22:00 -0400

si-local-file:///var/storage/secattach/20260813/26923140.html

Form SCHEDULE 13G/A PAVmed Inc. Filed by: NAGELBERG DAVID S

Thu, 13 Aug 2026 19:22:00 -0400

si-local-file:///var/storage/secattach/20260813/26923140.html

Form 10-Q PAVmed Inc. For: Jun 30

Thu, 13 Aug 2026 17:04:00 -0400

si-local-file:///var/storage/secattach/20260813/26922579.html

Form 10-Q PAVmed Inc. For: Jun 30

Thu, 13 Aug 2026 17:04:00 -0400

si-local-file:///var/storage/secattach/20260813/26922579.html

Lucid Diagnostics Provides Business Update and Reports Second Quarter 2026 Financial Results

Thu, 13 Aug 2026 08:00:00 -0400

Recognized 2Q26 revenue of $1.5 million

Processed 2,770 EsoGuard ^® tests

Secured first laboratory benefit manager (LBM) EsoGuard coverage policy

Conference call and webcast to be held today, August 13, at 8:30 AM EDT

NEW YORK, Aug. 13, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM) ("PAVmed"), today provided a business update for the Company and reported financial results for the second quarter

Lucid Diagnostics Provides Business Update and Reports Second Quarter 2026 Financial Results

Thu, 13 Aug 2026 08:00:00 -0400

Recognized 2Q26 revenue of $1.5 million

Processed 2,770 EsoGuard ^® tests

Secured first laboratory benefit manager (LBM) EsoGuard coverage policy

Conference call and webcast to be held today, August 13, at 8:30 AM EDT

Lucid Diagnostics Provides Business Update and Reports Second Quarter 2026 Financial Results

Thu, 13 Aug 2026 08:00:00 -0400

Recognized 2Q26 revenue of $1.5 million

Processed 2,770 EsoGuard ^® tests

Secured first laboratory benefit manager (LBM) EsoGuard coverage policy

Conference call and webcast to be held today, August 13, at 8:30 AM EDT

Lucid Diagnostics Provides Business Update and Reports Second Quarter 2026 Financial Results

Thu, 13 Aug 2026 08:00:00 -0400

Recognized 2Q26 revenue of $1.5 million

Processed 2,770 EsoGuard ^® tests

Secured first laboratory benefit manager (LBM) EsoGuard coverage policy

Conference call and webcast to be held today, August 13, at 8:30 AM EDT

Lucid Diagnostics Provides Business Update and Reports Second Quarter 2026 Financial Results

Thu, 13 Aug 2026 08:00:00 -0400

Recognized 2Q26 revenue of $1.5 million

Processed 2,770 EsoGuard ^® tests

Secured first laboratory benefit manager (LBM) EsoGuard coverage policy

Conference call and webcast to be held today, August 13, at 8:30 AM EDT

Lucid Diagnostics Provides Business Update and Reports Second Quarter 2026 Financial Results

Thu, 13 Aug 2026 08:00:00 -0400

Recognized 2Q26 revenue of $1.5 million

Processed 2,770 EsoGuard ^® tests

Secured first laboratory benefit manager (LBM) EsoGuard coverage policy

Conference call and webcast to be held today, August 13, at 8:30 AM EDT

Lucid Diagnostics Provides Business Update and Reports Second Quarter 2026 Financial Results

Thu, 13 Aug 2026 08:00:00 -0400

Recognized 2Q26 revenue of $1.5 million

Processed 2,770 EsoGuard ^® tests

Secured first laboratory benefit manager (LBM) EsoGuard coverage policy

Conference call and webcast to be held today, August 13, at 8:30 AM EDT